新天地药业股份有限公司位于长葛经济技术开发区，专业从事医药中间体、原料药和制剂的研发、生产和销售。公司是全球左旋对羟基苯甘氨酸（生产阿莫西林原料药的主要原料）和对甲苯磺酸（生产多西环素原料药的主要原料）主要生产企业，并获国家知识产权局认定的专利密集产品。公司牵头和参与制定了左旋对羟基苯甘氨酸、左旋对羟基苯甘氨酸甲酯、对甲苯磺酸、乙醛酸等4个产品的行业标准，拥有关键生产技术13项发明专利，其中，左旋对羟基苯甘氨酸合成技术获得美英日印等8个国家发明授权。2022年11月，公司股票在深交所创业板上市（股票简称：新天地，股票代码：301277）。

       公司先后荣获国家级绿色工厂、国家知识产权优势企业、高新技术企业、中国质量诚信企业、河南省创新龙头企业、河南省技术创新示范企业、河南省绿色技术创新示范企业、河南省优秀民营企业（高成长性）等荣誉。

       公司锚定2025-2030发展战略，以“筑核铸链”（核心竞争力、一体化产业链）为主线，强力推进“产品系列化、技术平台化、管理数字化、创新智能化、市场国际化、品牌高端化”战略规划，公司依托北京、郑州两个研发平台，进一步集聚行业内高端人才和技术成果优势，围绕仿制药、创新药强链补链，加速生物医药产业高质量发展。

       NEWLAND PHARMACEUTICAL CO., LTD is located in Changge Economic and Technological Development Zone. It is specialized in R&D, production and sales of pharmaceutical intermediates, APIs and formulations.The company is a major global manufacturer of ‌D-p-Hydroxyphenylglycine‌ (the core raw material for producing amoxicillin API) and ‌p-Toluenesulfonic acid‌ (the core raw material for producing doxycycline API). Its products are recognized as patent-intensive products by the China National Intellectual Property Administration. The company has led and participated in the formulation of 4 industry standards for products including D-p-hydroxyphenylglycine, Methyl D-(-)-4-Hydroxyphenylclycinate, p-Toluenesulfonic acid and Glyoxylic Acid, and owns 13 invention patents for key production technologies. Among them, the synthesis technology of D-p-hydroxyphenylglycine has obtained invention authorization from 8 countries including the United States, the United Kingdom, Japan and India. In November 2022, the company's shares were listed on the ChiNext Board of the Shenzhen Stock Exchange (stock abbreviation: Xin Tiandi, stock code: 301277).

       The company has successively won honors such as National Green Factory, National Intellectual Property Advantage Enterprise, High-tech Enterprise, China Quality and Credit Enterprise, Henan Innovation Leading Enterprise, Henan Technology Innovation Demonstration Enterprise, Henan Green Technology Innovation Demonstration Enterprise, and Henan Excellent Private Enterprise (High Growth).

       Focusing on its development strategy for 2025-2030, the company takes "core building & chain strengthening" (core competitiveness, integrated industrial chain) as the main line, and vigorously promotes the strategic planning of "product serialization, technology platform, management digitalization, intelligent innovation, market internationalization, and high-end brand". Relying on two R&D platforms in Beijing and Zhengzhou, the company further gathers advantages of high-end talents and technical achievements in the industry, strengthens and complements the chain around generic drugs and innovative drugs, and accelerates the high-quality development of the biomedical industry.